LVGN 8201
Alternative Names: LVGN-8201Latest Information Update: 07 Jan 2022
At a glance
- Originator Lyvgen Biopharma
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Neoplasm antigen modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 06 Jan 2022 Research programme: LVGN 8201 - Lyvgen Biopharma is available for licensing as of 06 Jan 2022. https://www.lyvgen.com
- 06 Jan 2022 Early research in Cancer in China (Parenteral) as of January 2022 (Lyvgen Biopharma pipeline; January 2022)